Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
28 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
XTL Biopharmaceuticals Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'XTL Biopharmaceuticals Ltd. - Product Pipeline Review - 2014', provides an overview of the XTL Biopharmaceuticals Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of XTL Biopharmaceuticals Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of XTL Biopharmaceuticals Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of XTL Biopharmaceuticals Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the XTL Biopharmaceuticals Ltd.'s pipeline products Reasons to buy - Evaluate XTL Biopharmaceuticals Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of XTL Biopharmaceuticals Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the XTL Biopharmaceuticals Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of XTL Biopharmaceuticals Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of XTL Biopharmaceuticals Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of XTL Biopharmaceuticals Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 XTL Biopharmaceuticals Ltd. Snapshot 5 XTL Biopharmaceuticals Ltd. Overview 5 Key Information 5 Key Facts 5 XTL Biopharmaceuticals Ltd. - Research and Development Overview 6 Key Therapeutic Areas 6 XTL Biopharmaceuticals Ltd. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Out-Licensed Products 10 Out-Licensed Products/Combination Treatment Modalities 11 XTL Biopharmaceuticals Ltd. - Pipeline Products Glance 12 XTL Biopharmaceuticals Ltd. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 XTL Biopharmaceuticals Ltd. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 XTL Biopharmaceuticals Ltd. - Drug Profiles 15 edratide 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 SAM-101 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Recombinant Protein to Agonize Erythropoietin Receptor for Multiple Myeloma 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 PRT-0467 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 XTL Biopharmaceuticals Ltd. - Pipeline Analysis 19 XTL Biopharmaceuticals Ltd. - Pipeline Products by Target 19 XTL Biopharmaceuticals Ltd. - Pipeline Products by Route of Administration 20 XTL Biopharmaceuticals Ltd. - Pipeline Products by Molecule Type 21 XTL Biopharmaceuticals Ltd. - Pipeline Products by Mechanism of Action 22 XTL Biopharmaceuticals Ltd. - Recent Pipeline Updates 23 XTL Biopharmaceuticals Ltd. - Dormant Projects 24 XTL Biopharmaceuticals Ltd. - Discontinued Pipeline Products 25 Discontinued Pipeline Product Profiles 25 XTL-6865 25 BC-2125 25 bicifadine hydrochloride 25 edratide 25 XTL Biopharmaceuticals Ltd. - Locations And Subsidiaries 26 Head Office 26 Other Locations & Subsidiaries 26 Appendix 27 Methodology 27 Coverage 27 Secondary Research 27 Primary Research 27 Expert Panel Validation 27 Contact Us 28 Disclaimer 28
List of Tables XTL Biopharmaceuticals Ltd., Key Information 5 XTL Biopharmaceuticals Ltd., Key Facts 5 XTL Biopharmaceuticals Ltd. - Pipeline by Indication, 2014 7 XTL Biopharmaceuticals Ltd. - Pipeline by Stage of Development, 2014 8 XTL Biopharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2014 9 XTL Biopharmaceuticals Ltd. - Out-Licensed Products in Pipeline, 2014 10 XTL Biopharmaceuticals Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 11 XTL Biopharmaceuticals Ltd. - Phase II, 2014 12 XTL Biopharmaceuticals Ltd. - Phase I, 2014 13 XTL Biopharmaceuticals Ltd. - Preclinical, 2014 14 XTL Biopharmaceuticals Ltd. - Pipeline by Target, 2014 19 XTL Biopharmaceuticals Ltd. - Pipeline by Route of Administration, 2014 20 XTL Biopharmaceuticals Ltd. - Pipeline by Molecule Type, 2014 21 XTL Biopharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2014 22 XTL Biopharmaceuticals Ltd. - Recent Pipeline Updates, 2014 23 XTL Biopharmaceuticals Ltd. - Dormant Developmental Projects,2014 24 XTL Biopharmaceuticals Ltd. - Discontinued Pipeline Products, 2014 25 XTL Biopharmaceuticals Ltd., Subsidiaries 26
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.